Published in Am J Trop Med Hyg on June 01, 2007
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med (2008) 5.29
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J (2008) 2.41
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis (2009) 2.15
Clinical features of children hospitalized with malaria--a study from Bikaner, northwest India. Am J Trop Med Hyg (2010) 2.14
Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One (2010) 1.87
The anaemia of Plasmodium vivax malaria. Malar J (2012) 1.82
Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature. Malar J (2012) 1.72
An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis (2013) 1.72
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa. Malar J (2011) 1.66
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 1.63
Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One (2011) 1.55
Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis (2011) 1.47
Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children. Clin Infect Dis (2015) 1.42
Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity (2015) 1.25
Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One (2012) 1.23
Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect Immun (2009) 1.20
Blood-Stage Parasitaemia and Age Determine Plasmodium falciparum and P. vivax Gametocytaemia in Papua New Guinea. PLoS One (2015) 1.15
Red blood cell polymorphism and susceptibility to Plasmodium vivax. Adv Parasitol (2013) 1.15
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect Immun (2009) 1.11
Is Plasmodium vivax malaria a severe malaria?: a systematic review and meta-analysis. PLoS Negl Trop Dis (2014) 1.10
A Large Plasmodium vivax Reservoir and Little Population Structure in the South Pacific. PLoS One (2013) 1.07
Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect Immun (2014) 1.06
Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one? Infect Immun (2007) 1.05
A high force of plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in papua new guinean children. PLoS Negl Trop Dis (2013) 1.04
Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob Agents Chemother (2012) 1.02
Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans. PLoS One (2011) 1.01
Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One (2013) 1.01
Seeking treatment for symptomatic malaria in Papua New Guinea. Malar J (2010) 1.00
Severe anemia in Papua New Guinean children from a malaria-endemic area: a case-control etiologic study. PLoS Negl Trop Dis (2012) 1.00
The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS One (2012) 1.00
Plasmodium vivax populations are more genetically diverse and less structured than sympatric Plasmodium falciparum populations. PLoS Negl Trop Dis (2015) 0.98
Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection. Vaccine (2009) 0.96
High levels of genetic diversity of Plasmodium falciparum populations in Papua New Guinea despite variable infection prevalence. Am J Trop Med Hyg (2013) 0.96
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. PLoS Med (2012) 0.94
Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax. PLoS One (2011) 0.93
Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria. Front Microbiol (2014) 0.93
Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg (2016) 0.93
Rapid antigen detection tests for malaria diagnosis in severely ill Papua New Guinean children: a comparative study using Bayesian latent class models. PLoS One (2012) 0.92
Research challenges and gaps in malaria knowledge in Papua New Guinea. Acta Trop (2011) 0.92
Plasmodium malaria and antimalarial antibodies in the first year of life. Parasitology (2016) 0.89
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2014) 0.87
Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study. Malar J (2015) 0.86
Minimal association of common red blood cell polymorphisms with Plasmodium falciparum infection and uncomplicated malaria in Papua New Guinean school children. Am J Trop Med Hyg (2010) 0.86
Population genetic analysis of the Plasmodium falciparum 6-cys protein Pf38 in Papua New Guinea reveals domain-specific balancing selection. Malar J (2011) 0.86
Novel Cross-Border Approaches to Optimise Identification of Asymptomatic and Artemisinin-Resistant Plasmodium Infection in Mobile Populations Crossing Cambodian Borders. PLoS One (2015) 0.85
Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Antimicrob Agents Chemother (2015) 0.85
Estimating cytomegalovirus growth rates by using only a single point. J Virol (2013) 0.84
Heterogeneous distribution of Plasmodium falciparum drug resistance haplotypes in subsets of the host population. Malar J (2008) 0.84
Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection. Infect Immun (2015) 0.84
Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol (2016) 0.81
Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein. Int J Parasitol (2012) 0.81
Immunity to malaria in Plasmodium vivax infection: a study in central China. PLoS One (2012) 0.81
Acquired immunity in a holoendemic setting of Plasmodium falciparum and p. Vivax malaria. Am J Trop Med Hyg (2007) 0.81
Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria. Mol Cell Proteomics (2014) 0.81
Modeling the effects of relapse in the transmission dynamics of malaria parasites. J Parasitol Res (2011) 0.79
Identification of different malaria patterns due to Plasmodium falciparum and Plasmodium vivax in Ethiopian children: a prospective cohort study. Malar J (2016) 0.78
Complicated malaria symptoms associated with Plasmodium vivax among patients visiting health facilities in Mendi town, Northwest Ethiopia. BMC Infect Dis (2016) 0.77
Malaria epidemiology in Lihir Island, Papua New Guinea. Malar J (2013) 0.77
Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia. PLoS One (2016) 0.76
Plasmodium vivax infection: a major determinant of severe anaemia in infancy. Malar J (2016) 0.75
A Toll-like receptor-1 variant and its characteristic cellular phenotype is associated with severe malaria in Papua New Guinean children. Genes Immun (2015) 0.75
The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Sci Rep (2016) 0.75
Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. Infect Immun (2016) 0.75
Spatial Effects on the Multiplicity of Plasmodium falciparum Infections. PLoS One (2016) 0.75
Ultrasonographic assessment of splenic volume at presentation and after anti-malarial therapy in children with malarial anaemia. Malar J (2015) 0.75
Complicated malaria in children and adults from three settings of the Colombian Pacific Coast: A prospective study. PLoS One (2017) 0.75
The complex relationship of exposure to new Plasmodium infections and incidence of clinical malaria in Papua New Guinea. Elife (2017) 0.75
Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans R Soc Trop Med Hyg (1987) 6.58
Mixed-species malaria infections in humans. Trends Parasitol (2004) 6.01
The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg (1994) 4.34
Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med (1999) 4.18
Immune effector mechanisms in malaria. Parasite Immunol (2006) 3.43
High incidence of malaria in alpha-thalassaemic children. Nature (1996) 3.12
The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am J Trop Med Hyg (1986) 3.04
Field evaluation of enzyme-linked immunosorbent assays for Plasmodium falciparum and Plasmodium vivax sporozoites in mosquitoes (Diptera: Culicidae) from Papua New Guinea. J Med Entomol (1987) 2.45
Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am J Trop Med Hyg (2006) 2.42
The effect of distance from home on attendance at a small rural health centre in Papua New Guinea. Int J Epidemiol (1998) 2.41
Premunition in Plasmodium falciparum infection: insights from the epidemiology of multiple infections. Trans R Soc Trop Med Hyg (1999) 2.35
The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop Med Parasitol (1995) 2.24
The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends Parasitol (2004) 2.16
The interaction between Plasmodium falciparum and P. vivax in children on Espiritu Santo island, Vanuatu. Trans R Soc Trop Med Hyg (1997) 2.12
Genetic diversity and dynamics of plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. Parasitology (2000) 2.10
The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol (2002) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Human malaria transmission studies in the Anopheles punctulatus complex in Papua New Guinea: sporozoite rates, inoculation rates, and sporozoite densities. Am J Trop Med Hyg (1988) 1.89
Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis (2006) 1.82
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80
Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg (2002) 1.73
Mixed-species Plasmodium infections of humans. J Parasitol (1997) 1.69
Comparison between anopheline mosquitoes (Diptera: Culicidae) caught using different methods in a malaria endemic area of Papua New Guinea. Bull Entomol Res (2000) 1.67
Prospective risk of morbidity in relation to malaria infection in an area of high endemicity of multiple species of Plasmodium. Am J Trop Med Hyg (2001) 1.67
Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect Immun (2000) 1.64
Clinical immunity to malaria. Curr Mol Med (2006) 1.63
Associations of peak shifts in age--prevalence for human malarias with bednet coverage. Trans R Soc Trop Med Hyg (2001) 1.58
The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Ann Trop Med Parasitol (1995) 1.58
Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis (2002) 1.53
A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg (1999) 1.51
Immunity to asexual blood stage malaria and vaccine approaches. Immunol Cell Biol (2002) 1.51
Relationships between Plasmodium falciparum infection and morbidity in a highly endemic area. Parasitology (1994) 1.46
Age- and species-specific duration of infection in asymptomatic malaria infections in Papua New Guinea. Parasitology (2000) 1.46
Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children. Trop Med Int Health (1998) 1.43
A retrospective examination of reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg (2004) 1.38
Plasmodium vivax malaria vaccine development. Mol Immunol (2001) 1.36
Dynamics of malaria parasitaemia associated with febrile illness in children from a rural area of Madang, Papua New Guinea. Trans R Soc Trop Med Hyg (1994) 1.32
Genotyping of Plasmodium falciparum. PCR-RFLP analysis. Methods Mol Med (2002) 1.31
Polymerase chain reaction diagnosis and the changing pattern of vector ecology and malaria transmission dynamics in papua new Guinea. Am J Trop Med Hyg (2004) 1.28
Immune responses to asexual blood-stages of malaria parasites. Curr Mol Med (2006) 1.28
Effect of Plasmodium falciparum parasitemia density on hemoglobin concentrations among full-term, normal birth weight children in western Kenya, IV. The Asembo Bay Cohort Project. Am J Trop Med Hyg (2000) 1.27
Patterns of acquired anti-malarial immunity in Sri Lanka. Mem Inst Oswaldo Cruz (1994) 1.26
Does radical cure of asymptomatic Plasmodium falciparum place adults in endemic areas at increased risk of recurrent symptomatic malaria? Trop Med Int Health (2002) 1.06
Plasmodium ovale in a highly malaria endemic area of Senegal. Trans R Soc Trop Med Hyg (1999) 1.03
High-throughput identification of the predominant malaria parasite clone in complex blood stage infections using a multi-SNP molecular haplotyping assay. Am J Trop Med Hyg (2007) 1.00
Iron and infection in infancy--report on field studies in Papua New Guinea: 1. Demographic description and pilot surveys. Ann Trop Paediatr (1984) 0.80
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med (2008) 5.29
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell (2008) 3.80
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nat Med (2002) 3.29
Reported reasons for not using a mosquito net when one is available: a review of the published literature. Malar J (2011) 3.16
A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria. Nature (2005) 2.99
Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis (2008) 2.80
Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A (2010) 2.79
Clinical features and pathogenesis of severe malaria. Trends Parasitol (2004) 2.73
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med (2010) 2.61
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis (2012) 2.52
Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am J Trop Med Hyg (2006) 2.42
Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte. Cell Host Microbe (2011) 2.37
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A (2010) 2.25
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A (2003) 2.19
Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol (2008) 2.19
The global distribution of the Duffy blood group. Nat Commun (2011) 2.06
Plasmodium malariae and Plasmodium ovale--the "bashful" malaria parasites. Trends Parasitol (2007) 2.04
The future for blood-stage vaccines against malaria. Immunol Cell Biol (2009) 2.04
Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun (2003) 2.02
Molecular evidence for the localization of Plasmodium falciparum immature gametocytes in bone marrow. Blood (2013) 2.01
R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A (2003) 2.00
Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science (2012) 1.97
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest (2008) 1.96
Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem (2005) 1.95
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis (2009) 1.95
Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med (2007) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes. Am J Trop Med Hyg (2006) 1.92
Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. Proc Natl Acad Sci U S A (2010) 1.91
Extensive microsatellite diversity in the human malaria parasite Plasmodium vivax. Gene (2008) 1.89
Rise in malaria incidence rates in South Africa: a small-area spatial analysis of variation in time trends. Am J Epidemiol (2002) 1.88
Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. PLoS Med (2009) 1.87
Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One (2010) 1.87
Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics (2006) 1.86
Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis (2006) 1.82
MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol (2003) 1.82
Malaria in pregnancy and the endemicity spectrum: what can we learn? Trends Parasitol (2004) 1.81
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis (2010) 1.79
Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol (2006) 1.78
The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis (2008) 1.74
Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg (2002) 1.73
Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci U S A (2008) 1.73
Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol (2009) 1.72
Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet (2004) 1.71
NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J Immunol (2007) 1.69
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
Strategies for detection of Plasmodium species gametocytes. PLoS One (2013) 1.67
A sub-microscopic gametocyte reservoir can sustain malaria transmission. PLoS One (2011) 1.67
Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malar J (2009) 1.67
Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa. Malar J (2011) 1.66
The effects of maternal helminth and malaria infections on mother-to-child HIV transmission. AIDS (2005) 1.65
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother (2007) 1.64
Clinical immunity to malaria. Curr Mol Med (2006) 1.63
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 1.63
IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog (2009) 1.61
Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma. Cell Host Microbe (2007) 1.61
Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J (2010) 1.60
Insight into the early spread of chloroquine-resistant Plasmodium falciparum infections in Papua New Guinea. J Infect Dis (2005) 1.60
Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg (2007) 1.58
Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One (2011) 1.55
Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. Immunity (2003) 1.54
Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype. Mol Microbiol (2005) 1.54
Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One (2008) 1.53
Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis (2002) 1.53
Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol (2003) 1.52
Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites. Infect Immun (2010) 1.52
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.50